On Sunday and Monday, AstraZeneca unveiled the results of three studies in patients with forms of breast and gastric cancer. If approved, the regimens would treat an estimated 82,000 patients across ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

AstraZeneca, a major pharmaceutical company, has sued Utah’s Attorney General Derek Brown over a recently passed state law ...

Pharmaceutical giant AstraZeneca is suing Utah’s attorney general and insurance commissioner over a law passed during the ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

EU approves AstraZeneca’s Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL: Cambridge, UK Saturday, June 7, ...

The AstraZeneca PLC ADR AZN rose 1.64% to $73.00 Wednesday, on what proved to be an all-around mixed trading session for the ...

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the ...

AstraZeneca PLC closed 19.58% short of its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca CEO Pascal Soriot views the company's stock price — up just 10% year-to-date — as a marker of how he is doing. He ...